95 results
424B5
RVNC
Revance Therapeutics Inc
5 Mar 24
Prospectus supplement for primary offering
5:00pm
taxable disposition, which gain may be offset by certain U.S.-source capital losses of the Non-U.S. Holder (even though the Non-U.S. Holder
424B5
RVNC
Revance Therapeutics Inc
4 Mar 24
Prospectus supplement for primary offering
6:39am
be specified by an applicable income tax treaty, on gain realized upon the sale or other taxable disposition, which gain may be offset by certain U.S
8-K
EX-99.1
RVNC
Revance Therapeutics Inc
28 Feb 24
Provides Corporate Update
4:07pm
of $24.0 million and $84.0 million, respectively. Q4 DAXXIFY volume sold increased 22% over the third quarter, with revenue offset by a lower average selling
8-K
EX-10.1
RVNC
Revance Therapeutics Inc
13 Feb 24
Departure of Directors or Certain Officers
4:28pm
Termination, the Company reserves the right to offset the payment of any benefits under the Plan by the amount of such indebtedness. Such offset
8-K
EX-99.1
orqhv4r1ftsjmdd
8 Jan 24
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
8:01am
8-K
EX-99.1
mopbshkay
8 Nov 23
Provides Corporate Update
4:09pm
424B5
hqc0wm1
13 Sep 22
Prospectus supplement for primary offering
9:13pm
424B5
0ja6me3 c8v
12 Sep 22
Prospectus supplement for primary offering
4:09pm
8-K
EX-99.1
568l6 e2438nigb
10 May 22
Revance Reports First Quarter 2022 Financial Results, Provides Corporate Update
4:13pm
8-K
EX-99.1
alozo ba4
28 Feb 22
Provides Corporate Update
4:10pm